Refractory T cell Non-Hodgkin Lymphoma
Showing 1 - 25 of >10,000
T-cell Non-Hodgkin's Lymphoma Trial (CD147- CAR T cells)
Not yet recruiting
- T-cell Non-Hodgkin's Lymphoma
- CD147- CAR T cells
- (no location specified)
Aug 1, 2022
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)
Not yet recruiting
- T-cell Lymphoma
- +10 more
-
Chicago, IllinoisRush University Medical Center
Oct 24, 2022
Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,
Not yet recruiting
- Non-hodgkin Lymphoma
- +9 more
- CD79b-19 CAR T cells
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 6, 2023
B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)
Recruiting
- B-Cell Non Hodgkin Lymphoma
- B-Cell Acute Lymphoblastic Leukemia
- anti-CD19 CAR T-cells
-
Hanoi, VietnamVinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin
Active, not recruiting
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- +16 more
- 6,8-bis(benzylthio)octanoic acid
- bendamustine hydrochloride
-
Winston-Salem, North Carolina
- +1 more
Apr 8, 2022
Relapsed or Refractory B Cell Non-Hodgkin Lymphoma Trial (C-CAR066)
Not yet recruiting
- Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
- (no location specified)
Mar 23, 2023
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Leukemia, Acute Lymphoblastic, Lymphoma, Non-Hodgkin Trial in Ribeirao Preto (CART-19)
Not yet recruiting
- Leukemia, Acute Lymphoblastic
- Lymphoma, Non-Hodgkin
- CART-19
-
Ribeirao Preto, Sao Paulo, BrazilRibeirao Preto School of Medicine, University of Sao Paulo
Oct 23, 2023
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell
Active, not recruiting
- Recurrent Anaplastic Large Cell Lymphoma
- +10 more
- Pembrolizumab
- Romidepsin
-
Houston, TexasM D Anderson Cancer Center
Jan 30, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
B-cell Non Hodgkin Lymphoma Trial (Odronextamab, Loncastuximab tesirine, Rituximab)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Odronextamab
- +8 more
- (no location specified)
Aug 7, 2023
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022
B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Charleston (Cyclophosphamide injection, Fludarabine
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Cyclophosphamide injection
- +2 more
-
Charleston, South CarolinaHollings Cancer Center at Medical University of South Carolina
Jan 18, 2023
Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in
Active, not recruiting
- Hematopoietic Cell Transplantation Recipient
- +3 more
- Allogeneic Bone Marrow Transplantation
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- (no location specified)
Sep 19, 2023
Relapsed or Refractory Mantle Cell Lymphoma (MCL) Trial in Duarte (BAFFR-CAR T cells)
Recruiting
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- BAFFR-CAR T cells
-
Duarte, CaliforniaCity of Hope Medical Center
Oct 18, 2022
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)
Not yet recruiting
- Lymphoma, Non-Hodgkin Lymphoma, B-Cell
- BAFF CAR-T
- (no location specified)
Aug 16, 2022
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma Trial in Winston-Salem (CPI 613, Bendamustine)
Recruiting
- Relapsed T-Cell Lymphoma
- +2 more
- CPI 613
- Bendamustine
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Aug 27, 2021
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides Trial in United
Recruiting
- Folliculotropic Mycosis Fungoides
- +7 more
- Durvalumab
- +2 more
-
Duarte, California
- +3 more
Jan 12, 2023
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL Trial in Seattle (biological,
Recruiting
- Recurrent B-Cell Non-Hodgkin Lymphoma
- +20 more
- Chimeric Antigen Receptor T-Cell Therapy
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 11, 2022
Non Hodgkin's Lymphoma Trial in Beijing (TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T),
Not yet recruiting
- Non Hodgkin's Lymphoma
- TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T cell (ATHENA CAR-T)
- +2 more
-
Beijing, China
- +2 more
Aug 23, 2023
Non Hodgkin Lymphoma Trial in Aurora (UCD19 CAR T Cells)
Active, not recruiting
- Non Hodgkin Lymphoma
- UCD19 CAR T Cells
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 1, 2022